secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117099
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone reports Q3 operating loss $14.6M; Phase 3 RAPID trial meets primary efficacy endpoint
--------------------------------------------------------------------------------

- Phase 3 RAPID trial met primary endpoint: 64.3% etripamil vs 31.2% placebo conversion to sinus rhythm within 30 min (HR=2.62, p<0.001).
- Additional AHA data: conversion rates ~74% at 60 min, ~80% at 90 min; median time to conversion 17.2 min for etripamil.
- Company plans to submit NDA for etripamil in PSVT to FDA in mid-2023, pending agency feedback.
- Cash, cash equivalents, and short-term investments $77.2M as of Sept 30, 2022; expected to fund operations through 2023.
- Successful RAPID results triggered $3.5M milestone payment from partner Ji Xing; total potential milestones up to $107.5M in Greater China.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922117099/0001104659-22-117099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922117099/tm2230245d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer